Chemical Modeling against KRAS
October 31, 2023 | Terry Sharrer
“For the current study, Lito led a group that included researchers at Revolution Medicines, Inc., a Redwood City, CA-based company. The team designed several molecules they showed to have the same inhibitory activity. They began by creating a molecule inspired by sanglifehrin A, a natural product known to bind to cyclophilin A (CYPA). CYPA is a cellular chaperone, which means it helps with the folding and unfolding of proteins. The researchers combined their molecule with CYPA, creating a sticky surface with an affinity for binding to KRAS. They refer to this process as chemical remodeling. They used the remodeled CYPA-molecule complex in their experiments.” MORE
Image Credit: InsidePrecisionMedicine